Breaking News Instant updates and real-time market news.

2018-10-02 21:15:46 GWPH GW Pharmaceuticals $162.57 -4.54 (-2.72%) 21:15 10/02/18 10/02 21:15 10/02/18 21:15	GW Pharmaceuticals 1.9M share Secondary priced at $158.00 Goldman Sachs, Morgan Stanley, JPMorgan and Cowen acted as joint book running managers for the offering.	03 Oct
GWPH GW Pharmaceuticals $162.57 -4.54 (-2.72%) 09/07/18 MSCO 09/07/18 INITIATION Target $197 MSCO Overweight GW Pharmaceuticals resumed with an Overweight at Morgan Stanley Morgan Stanley analyst David Lebowitz resumed coverage of GW Pharmaceuticals with an Overweight rating and $197 price target, stating that he expects a strong launch for Epidiolex for Dravet and Lenox-Gastaut syndromes once the DEA has officially rescheduled the marijuana-based therapy as being acceptable for medicinal use. He projects 2019 Epidiolex franchise sales of $72M growing to $1.3B by 2025, Lebowitz tells investors. 09/19/18 MSCO 09/19/18 NO CHANGE Target $197 MSCO Overweight Launch of GW Pharmaceuticals' Epidiolex 'likely imminent,' says Morgan Stanley Morgan Stanley analyst David Lebowitz noted that the FDA approved GW Pharmaceuticals' cannabis-based Epidiolex for the treatment of two ultra rare forms of epilepsy on June 25 and the Drug Enforcement Agency rescheduling of the therapy to allow medicinal use was expected to take place within 90 days, or by about September 23. He sees the U.S. launch being "imminent," pending the rescheduling, and said it will be a catalyst for GW Pharmaceuticals given that Epidiolex is the first FDA approved cannabinoid-based therapy. The analyst, who sees the drug being a blockbuster with off label use driving $1.3B in sales by 2025, reiterates his Overweight rating and $197 price target on GW Pharmaceuticals shares. 09/27/18 CANT 09/27/18 NO CHANGE Target $211 CANT Overweight Cantor says Epidiolex DEA rescheduling 'best possible outcome' for GW Pharma Cantor Fitzgerald analyst Elemer Piros noted that the DEA rescheduled Epidiolex to Schedule V, the lowest ranked class, from being a Schedule I drug, as he expected. He believes this rescheduling classification is "the best possible outcome" for GW Pharmaceuticals and checks off the last box as the company prepares to launch the drug within six weeks. Piros reiterates an Overweight rating and $211 price target on GW Pharmaceuticals shares. 09/28/18 MSCO 09/28/18 NO CHANGE Target $240 MSCO Overweight GW Pharmaceuticals price target raised to $240 from $197 at Morgan Stanley Morgan Stanley analyst David Lebowitz raised his price target on GW Pharmaceuticals shares to $240 from $197 following the DEA's assignment of Epidiolex to Schedule V, which he said was a better classification than he expected. Stating that the favorable scheduling should enable a strong launch, Lebowitz increased his Epidiolex estimates and maintains an Overweight rating on GW Pharmaceuticals.

2018-10-02 21:15:46

GWPH

GW Pharmaceuticals

$162.57: -4.54 (-2.72%)

21:15

10/02/18

10/02

21:15

10/02/18

21:15

GW Pharmaceuticals 1.9M share Secondary priced at $158.00

Goldman Sachs, Morgan Stanley, JPMorgan and Cowen acted as joint book running managers for the offering.

03
Oct

GWPH GW Pharmaceuticals

$162.57: -4.54 (-2.72%)

09/07/18: MSCO

09/19/18: MSCO

09/27/18: CANT

09/28/18: MSCO

TODAY'S FREE FLY STORIES

SCI Service Corp. $42.31 -0.42 (-0.98%) 11:17 02/21/19 02/21 11:17 02/21/19 11:17 Hot Stocks	Service Corp. raises quarterly cash dividend 6% to 18c per share » Service Corporation… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Mar
$NSD NASDAQ Market Internals $0.00 (0.00%) 11:17 02/21/19 02/21 11:17 02/21/19 11:17 Technical Analysis	NASDAQ market internals summary » Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
$NYE NYSE Market Internals $0.00 (0.00%) 11:16 02/21/19 02/21 11:16 02/21/19 11:16 Technical Analysis	NYSE market internals summary » Volume is average for… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
11:15 02/21/19 02/21 11:15 02/21/19 11:15 General news	Breaking General news story » 8-Week Bill Auction to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
11:15 02/21/19 02/21 11:15 02/21/19 11:15 General news	Breaking General news story » 4-Week Bill Auction to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial

GS Goldman Sachs $197.12 -1.49 (-0.75%) 11:10 02/21/19 02/21 11:10 02/21/19 11:10 Initiation	Goldman Sachs initiated » Odeon's Dick Bove… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Feb 03 Mar 12 Mar
11:10 02/21/19 02/21 11:10 02/21/19 11:10 General news	Energy Action: NYMEX crude » Energy Action: NYMEX… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
DK Delek US $36.95 -0.13 (-0.35%) 11:10 02/21/19 02/21 11:10 02/21/19 11:10 Options	Delek US draws upside call buyers as shares slip off early highs » Delek US draws upside… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
11:10 02/21/19 02/21 11:10 02/21/19 11:10 General news	Existing home sales fell 1.2% in January to 4.99 M, a 3-year low » Existing home sales fell… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
11:08 02/21/19 02/21 11:08 02/21/19 11:08 General news	3-Month Bill Announcement CUSIP Number data reported » 3-Month Bill Announcement… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial

MNST Monster Beverage $58.64 -0.07 (-0.12%) 11:07 02/21/19 02/21 11:07 02/21/19 11:07 Options	Monster Beverage option volume spikes to 3X daily average amid active trading » Monster Beverage option… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Feb
LIVN LivaNova $98.56 -1.32 (-1.32%) 11:07 02/21/19 02/21 11:07 02/21/19 11:07 Recommendations	LivaNova analyst commentary » Piper says Japanese… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Feb 06 Mar 07 May 08 May 09 May
UBCP United Bancorp $10.95 (0.00%) 11:04 02/21/19 02/21 11:04 02/21/19 11:04 Hot Stocks	United Bancorp raises quarterly cash dividend to 13.25c per share » The Board of Directors of… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LIVN LivaNova $98.59 -1.29 (-1.29%) 11:03 02/21/19 02/21 11:03 02/21/19 11:03 Hot Stocks	LivaNova announces national reimbursement in Japan for Perceval valve for AVD » LivaNova announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Feb 06 Mar 07 May 08 May 09 May
KO Coca-Cola $45.48 0.36 (0.80%) 11:03 02/21/19 02/21 11:03 02/21/19 11:03 Hot Stocks	Coca-Cola announces new share repurchase program for up to 150M shares » The Coca-Cola board… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	21 Feb 03 Mar

KO Coca-Cola $45.49 0.37 (0.82%) 11:02 02/21/19 02/21 11:02 02/21/19 11:02 Hot Stocks	Coca-Cola raises quarterly dividend to 40c per share from 39c per share » The Coca-Cola board… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	21 Feb 03 Mar
11:00 02/21/19 02/21 11:00 02/21/19 11:00 General news	EIA natural gas storage change for week ending February 15 » Earlier, gas inventories… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
11:00 02/21/19 02/21 11:00 02/21/19 11:00 General news	Crude inventories for week of February 15 » Crude oil inventories… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial
KR Kroger $28.82 0.07 (0.24%) 11:00 02/21/19 02/21 11:00 02/21/19 11:00 Options	One-day call buyers in Kroger » One-day call buyers in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Mar 07 Mar
UAA Under Armour $21.26 -0.02 (-0.09%) , UA Under Armour $19.22 0.025 (0.13%) 10:52 02/21/19 02/21 10:52 02/21/19 10:52 Periodicals	Under Armour CEO questioned by board about ties with MSNBC anchor, WSJ says » A number of current and… UAA Under Armour $21.26 -0.02 (-0.09%) UA Under Armour $19.22 0.025 (0.13%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Mar 06 Mar

10:50 02/21/19 02/21 10:50 02/21/19 10:50 General news	U.S. corporate bond update: issuance continues apace today » U.S. corporate bond… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial
COUP Coupa Software $92.39 -1.36 (-1.45%) 10:50 02/21/19 02/21 10:50 02/21/19 10:50 Options	Short-term hedge opened in Coupa Software » Short-term hedge opened… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Mar 11 Mar 12 Mar 12 Mar
10:50 02/21/19 02/21 10:50 02/21/19 10:50 General news	FX Action: USD-JPY » FX Action: USD-JPY has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
OHRP Ohr Pharmaceutical $2.01 (0.00%) 10:47 02/21/19 02/21 10:47 02/21/19 10:47 Hot Stocks	Ohr Pharmaceutical regains compliance with Nasdaq listing requirements » Ohr Pharmaceutical… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IMDZ Immune Design $5.81 4.385 (307.72%) , MRK Merck $79.79 0.35 (0.44%) 10:46 02/21/19 02/21 10:46 02/21/19 10:46 Downgrade	Immune Design, Merck rating change » Immune Design downgraded… IMDZ Immune Design $5.81 4.385 (307.72%) MRK Merck $79.79 0.35 (0.44%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	05 Mar 11 Apr 18 May 17 Jun

Events

Earnings calls, analyst events, roadshows and more

Today at 11:30

8-Week Bill Auction Government Event
Today at 11:30

4-Week Bill Auction Government Event
EIG
Today at 11:30

Employers Holdings - EIG Conference Calls
JACK
Today at 11:30

Jack in the Box - JACK Conference Calls
TTC
Today at 11:30

Toro Company - TTC Conference Calls
STOR
Today at 12:00

Store Capital - STOR Conference Calls
HOLX
Today at 12:30

Hologic Firm Sponsored Meetings

William Blair Offices - 666 Fifth Ave, New York, NY
Today at 13:00

30-Year TIPS Auction Government Event
SJW
Today at 13:00

SJW Corp. - SJW Conference Calls
KALU
Today at 13:00

Kaiser Aluminum - KALU Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	AI X AI Arlington Asset Investment Spot Secondary Managers: Morgan Stanley & JMP Securities Priced at: $8.33 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ARR X ARR ARMOUR Residential Spot Secondary Managers: Morgan Stanley & Barclays, Citi, Credit Suisse, Goldman Sachs & JPMorgan Priced at: $20.33 7.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CPT X CPT Camden Property Spot Secondary Managers: BofA/Merrill & Deutsche Bank Priced at: $97.85 3.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NRZ X NRZ New Residential Spot Secondary Managers: Morgan Stanley, Credit Suisse & JPMorgan Priced at: $16.50 40.3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OVID X OVID Ovid Therapeutics Spot Secondary Managers: Cowen & William Blair Priced at: $2.00 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SNNA X SNNA Sienna Biopharmaceuticals Spot Secondary Managers: Cowen & BMO Capital Priced at: $2.50 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	RWLK X RWLK ReWalk Robotics Spot Secondary Managers: H.C. Wainwright Priced at: $.23 19M Shares
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

GW Pharmaceuticals 1.9M share Secondary priced at $158.00

TODAY'S FREE FLY STORIES

Get Full Fly Access